

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Yvonne Man-yee Chen et al. Serial No.: 09/723,185 Filed: November 27, 2000 For: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES	Group Art Unit: 1647 Examiner: D. Romero
	CERTIFICATION OF HAND DELIVERY I hereby certify that this correspondence, was hand delivered to the Assistant Commissioner of Patents, Washington, D.C. 20231. Date: <u>2/22/02</u> <u>R.M.</u>

RECEIVED
 FEB 28 2002
 TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

Assistant Commissioner of Patents
 Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	19	-	51	0	18	\$0.00
Independent	2	-	4	0	80	\$0.00
___ Multiple dependent claim(s), if any					270	\$0.00
Total Fee Calculation						\$0.00

☒ No additional fee is required.

☐ The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$. **A duplicate copy of this transmittal is enclosed.**

☐ Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,
 GENENTECH, INC.

Date: February 20, 2002

By: Janet E. Hasak
 Janet E. Hasak, Reg. No. 28,616
 Telephone No. (650) 225-1896



09157

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Chen et al.

Serial No. 09/723,185

Filed: November 27, 2000

For: INSULIN-LIKE GROWTH
FACTOR AGONIST MOLECULES

Group Art Unit: 1647

Examiner: David S. Romeo

CERTIFICATION OF HAND DELIVERY

I hereby certify that this correspondence,
was hand delivered to the Assistant
Commissioner of Patents, Washington, D.C.
20231.Date: 2/22/02
R.M.SECOND PRELIMINARY AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

1. Replace the first two paragraphs on page 1 (the original and the one introduced by the transmittal form) with one paragraph as follows:

B1 This is a continuation of co-pending application U.S. Ser. No. 09/337,227 filed June 22, 1999, which is a continuation-in-part application of co-pending U.S. Ser. No. 09/052,888 filed March 31, 1998, now U.S. Pat. No. 6,251,865, which is a continuation-in-part application of U.S. Ser. No. 08/825,852 filed April 4, 1997, issued as U.S. Patent Number 6,121,416, which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC §120.

2. Replace the first full paragraph on page 2 (lines 4-19) with the following paragraph:

B2 Like GH, IGF-I is a potent anabolic protein. See Tanner et al., Acta Endocrinol., 84: 681-696 (1977); Uthne et al., J. Clin. Endocrinol. Metab., 39: 548-554 (1974). See also Ross et al., Intensive

02 FEB 22 PM 12:33

RECEIVED
TECH CENTER 1600/2900RECEIVED
FEB 28 2002
TECH CENTER 1600/2900